Latest News in the pharma Industry

Research & Development

New service delivers streamlined pathway for Phase I trial milestones

New service delivers streamlined pathway for Phase I trial milestones

12 Sep 2017

Whether you're a small, virtual firm or Big Pharma, Recipharm Pathway to Clinic can remove the complexity out of first in human projects.

Read more 
Opdivo + Yervoy combination demonstrated superior overall survival in patients with kidney cancer

Opdivo + Yervoy combination demonstrated superior overall survival in patients with kidney cancer

10 Sep 2017

The combination therapy reduced the risk of death by 37% versus standard of care, sunitinib, in intermediate- and poor-risk patients.

Read more 
Monthly migraine days significantly reduced with erenumab

Monthly migraine days significantly reduced with erenumab

10 Sep 2017

The drug is the first and only fully human monoclonal antibody of its kind, uniquely designed to specifically block the CGRP receptor, which plays a critical role in activation of migraine.

Read more 
Vectura and Pulmatrix sign branded generic tiotropium bromide development agreement

Vectura and Pulmatrix sign branded generic tiotropium bromide development agreement

6 Sep 2017

Major new tiotropium bromide DPI development programme accelerated through licensing of Pulmatrix technology.

Read more 
Life-extending pancreatic cancer medicine recommended by NICE in final guidance

Life-extending pancreatic cancer medicine recommended by NICE in final guidance

6 Sep 2017

The pivotal Phase III study demonstrated that treatment with Abraxane in combination with gemcitabine can offer patients a median overall survival improvement of 1.8 months.

Read more 
Landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS

Landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS

6 Sep 2017

PARADIGMS is a first of its kind study in pediatric MS. Other current treatments have not been evaluated in head to head trials specifically designed for children and adolescents.

Read more 
SGS Clinical Research strengthens its consultancy service to accelerate drugs through early phase development

SGS Clinical Research strengthens its consultancy service to accelerate drugs through early phase development

5 Sep 2017

Company consolidates its consultancy portfolio into a single, comprehensive offering.

Read more 
Midatech submits MTD201 CTA filing for first in human study in carcinoid cancer and acromegaly

Midatech submits MTD201 CTA filing for first in human study in carcinoid cancer and acromegaly

4 Sep 2017

Midatech on track to start clinical development with MTD201 in Q4 2017.

Read more 
Bayer submits BLA in the for BAY94-9027 – a long-acting factor VIII for the treatment of hemophilia A

Bayer submits BLA in the for BAY94-9027 – a long-acting factor VIII for the treatment of hemophilia A

3 Sep 2017

Pivotal studies with BAY94-9027 showed that bleed protection was achieved with extended dosing intervals.

Read more 
Xeno-free cell culture medium for regenerative medicine research

Xeno-free cell culture medium for regenerative medicine research

31 Aug 2017

StemFit Basic02 offers superior and stable growth performance, high colony forming efficiency and robust scalable cell expansion.

Read more 
AstraZeneca and Takeda collaborate to develop and commercialise MEDI1341 for Parkinson’s disease

AstraZeneca and Takeda collaborate to develop and commercialise MEDI1341 for Parkinson’s disease

31 Aug 2017

MEDI1341 has the potential to achieve a better efficacy and safety profile than other alpha-synuclein antibodies.

Read more 
Phase III study confirms Kyprolis regimen extends overall survival In patients with relapsed multiple myeloma

Phase III study confirms Kyprolis regimen extends overall survival In patients with relapsed multiple myeloma

31 Aug 2017

ENDEAVOR study long-term data show Kyprolis and dexamethasone reduced the risk of death by 24% versus Velcade and dexamethasone.

Read more